Anteris Technologies Global Corp (NASDAQ: AVR) is a medical technology company developing a transcatheter heart valve for the treatment of aortic stenosis. The company is in the development stage and generates only small amounts of revenue, having incurred net losses each year since inception as of the FY2025 10-K filed February 26, 2026. Its primary asset is the DurAVR THV, a biomimetic transcatheter aortic valve replacement device made from a single piece of ADAPT anti-calcification tissue, paired with the ComASUR balloon-expandable delivery system. As of December 2025, more than 130 patients had been implanted with the DurAVR THV worldwide. The company is headquartered in Queensland, Australia, and lists its shares on The Nasdaq Global Market. Anteris completed its initial public offering in December 2024 following a reorganization. The TAVR market the company targets is projected by FMI to reach $9.9 billion globally for severe aortic stenosis procedures and $2.5 billion for valve-in-valve procedures by 2028.

Revenue model

Anteris is a development-stage company with no meaningful commercial revenue as of the FY2025 filing. Revenue is described as small amounts, with no product commercially approved or generating recurring sales at the time of the filing.

Products and services

DurAVR THV: a transcatheter heart valve made from a single piece of ADAPT-treated xenograft tissue, designed for minimally invasive aortic valve replacement. ADAPT tissue technology: a proprietary anti-calcification tissue processing platform, demonstrated to be calcium-free for up to 10 years post-procedure and used in over 55,000 patients globally across other indications. ComASUR Delivery System: a balloon-expandable catheter system designed for precise commissure-aligned placement of the DurAVR THV.

Customers and end markets

End patients are adults with severe aortic stenosis undergoing transcatheter aortic valve replacement. Procedural customers are interventional cardiologists and cardiac surgeons at hospital systems. The company is conducting clinical trials in the United States and Europe.

Value-chain role

Medical device developer and manufacturer. Anteris designs, develops, and manufactures its own heart valve and delivery system, with manufacturing scale-up and clean room expansion underway as of the FY2025 filing period.

Geographic exposure

Headquartered in Queensland, Australia. Clinical activity spans the United States and Europe. Shares listed on Nasdaq in the United States; CDIs also issued.

Source: SEC 10-K, filed 2026-02-26

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies